Operation Warp Speed and the National Institutes of Health have developed two master protocols for COVID-19 monoclonal antibody clinical trials, FDA drug center director Janet Woodcock told reporters on a press call Monday (July 13). One protocol will test the use of monoclonal antibodies in the outpatient setting and another is for inpatient use. They’re both scheduled to start testing this month. Woodcock said the Operation Warp Speed team hopes to have data on the effectiveness of the antibodies by...